Zacks Research Brokers Raise Earnings Estimates for Exelixis

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Exelixis in a note issued to investors on Monday, March 3rd. Zacks Research analyst E. Bagri now expects that the biotechnology company will earn $0.47 per share for the quarter, up from their prior forecast of $0.46. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2027 earnings at $3.20 EPS.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Several other equities research analysts also recently issued reports on the stock. Barclays raised their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price for the company. in a research note on Monday, February 24th. Finally, Stephens reiterated an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $38.21 on Wednesday. Exelixis has a 52-week low of $20.14 and a 52-week high of $39.30. The company has a market capitalization of $10.69 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company has a 50-day simple moving average of $34.81 and a 200 day simple moving average of $31.91.

Institutional Trading of Exelixis

A number of hedge funds have recently added to or reduced their stakes in EXEL. Invesco Ltd. boosted its position in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after buying an additional 3,001,204 shares in the last quarter. Norges Bank acquired a new stake in Exelixis in the fourth quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec boosted its position in Exelixis by 330.4% in the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock valued at $82,730,000 after buying an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Exelixis by 104.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock worth $105,208,000 after purchasing an additional 1,613,482 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christopher J. Senner sold 29,314 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 over the last three months. 2.85% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.